65020-70-4

Usage

Uses

Used in Pharmaceutical Research and Development:
4-(4-Fluorophenyl)-1H-imidazole is used as a compound with potential biological activities for the development of new drugs and therapeutics. Its antifungal and antimicrobial properties make it a promising candidate for treating various infections and diseases.
Used in Drug Synthesis:
In the pharmaceutical industry, 4-(4-Fluorophenyl)-1H-imidazole is utilized as a key building block in the synthesis of a variety of drugs. Its unique structure allows for the creation of new compounds with potential therapeutic applications.
Used in Antifungal and Antimicrobial Agents:
4-(4-Fluorophenyl)-1H-imidazole is employed as an active ingredient in antifungal and antimicrobial agents, leveraging its inherent biological activities to combat fungal and microbial infections.

Upstream product

• 766-98-3 1-ethynyl-4-fluorobenzene 
• 77287-34-4 formamide 
• 403-29-2 2-bromo-4'-fluoroacetophenone 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 1244039-76-6 C₁₄H₁₁FN₄S 
• 1150847-15-6 (4-(4-fluorophenyl)-1H-imidazol-1-yl)methanol 
• 670-95-1 4-Phenylimidazole 
• 1615729-91-3 4-(2-(4-(4-fluorophenyl)-1H-imidazol-1-yl)ethyl)morpholine 
• 1615729-70-8 tert-butyl 4-(4-(4-fluorophenyl)-1H-imidazol-1-yl)piperidine-1-carboxylate 
• 926659-96-3 (S)-1-((1-(tert-butyldiphenylsilyloxy))but-3-en-2-yl)-4-(4-fluorophenyl)-1H-imidazole 
• 1046136-24-6 5-(4-fluorophenyl)-1-(2-triisopropylsilanyl)-1H-imidazole 
• 1046136-19-9 4-(4-fluorophenyl)-1-(2-triisopropylsilanylethynyl)-1H-imidazole 

Relevant academic research and scientific papers

Preparation of Imidazole Derivatives via Bisfunctionalization of Alkynes Catalyzed by Ruthenium Carbonyl

A one-step, oxidative bisfunctionalization of alkynes to generate cis -enediol diacetates catalyzed by ruthenium carbonyl (triruthenium dodecacarbonyl) is presented. The reaction was performed using the alkyne, (diacetoxyiodo)benzene, Ru 3 (CO) 12 as the catalyst, and toluene as the solvent at 100 °C to give the cis -enediol diacetates in up to 82percent yields. This method overcomes the shortcomings of existing methods, such as tedious reaction steps, substrate limitations, and the use of toxic reagents. Furthermore, the reaction of module cis -enediol diacetates with ammonium carbonate [(NH 4) 2 CO 3 ] in an alcohol solvent gave imidazole derivatives in 37-84percent yields, thus providing a simple and mild new method for the synthesis of imidazole compounds.

PHARMACEUTICAL COMPOUNDS

The invention relates to compounds and compositions for inhibiting the enzyme fatty acid amide hydrolase (FAAH), the use of the compounds in therapy and, in particular, for treating or preventing conditions whose development or symptoms are linked to subs

NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF-KAPPAB ACITIVITY AND USE THEREOF

Disclosed are compounds of Formula (I) wherein: one of A and D is —N— and the other of A and D is —C—; or enantiomers, diastereomers, or pharmaceutically-acceptable salts thereof. Also disclosed are methods of using such compounds to modulate the function

Novel synthesis of the hexahydroimidazo[1,5b]isoquinoline scaffold: Application to the synthesis of glucocorticoid receptor modulators

The first stereoselective synthesis of the hexahydroimidazo[1,5b] isoquinoline (HHII) scaffold as a surrogate for the steroidal A-B ring system is described. The structure-activity relationships of the analogs derived from this scaffold show that the basic imidazole moiety is tolerated by the glucocorticoid receptor (GR) in terms of binding affinity, although the partial agonist activity in the transrepressive assays depends on the substitution pattern on the B-ring.More importantly, most compounds in the HHII series bearing a tertiary alcohol moiety on the B-ring are either inactive or significantly less active in inducing GR-mediated transactivation, thus displaying a "dissociated" pharmacology in vitro. 2010 American Chemical Society.

Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase

Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. With the goal of developing more potent IDO in

Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists

An imidazolylpyrimidine was identified in a CXCR2 chemokine receptor antagonist screen and was optimized for potency, in vitro metabolic stability, and oral bioavailability. It was found that subtle structural modification within the series affected the o